NeurAxis (NRXS) Q2 2026 Earnings Call Transcript
NeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The call updates traders on reimbursement progress (prior authorization rate, covered lives), commercial traction (ordering accounts, revenue per account), and financial trajectory (operating loss, cash on hand, burn rate, ATM facility status).
Market read
Fresh quarterly KPIs and cash/burn guidance details can drive re-pricing versus prior expectations, especially for reimbursement-driven medtech adoption stories.
What to watch
Management expects cash burn to increase in H2 and operating expenses to rise (sales, marketing, clinical research), so investors may re-rate the stock on financing risk even if reimbursement metrics improve.
Background
NeurAxis is implementing Category 1 CPT code coverage for PENFS and transitioning toward commercial execution, with emphasis on payer acceptance and VA market penetration.
Ticker impact
NeurAxis reported Q2 2026 revenue of $1.928M (+116% YoY) and an EPS loss of $0.19, citing payer mix shift and Category 1 CPT implementation.
Likely near-term support if investors focus on accelerating reimbursement-driven unit economics, but upside may be capped by rising operating loss and management’s expectation of higher H2 cash burn.
Multiple disclosed KPIs improved (ASP +28%, gross margin +230 bps, unit deliveries +60% QoQ/period, prior auth rate 31% vs 12%), but operating loss increased and management flagged higher H2 burn and adoption bottlenecks (hospital capacity, state CPT fee schedule gaps).
Market effects
Reimbursement and CPT-code adoption dynamics remain a key swing factor for neuromodulation/medtech adoption, reinforcing how payer coverage can rapidly change unit economics.
VA-focused commercial execution could concentrate demand in federal healthcare channels, potentially affecting regional hospital adoption timelines.
Limited direct global relevance; the disclosed drivers are US payer coding and Medicaid/VA coverage mechanics.
Counterpoint
The growth narrative may be partly mix-driven (full reimbursement payers) while underlying adoption is still constrained by hospital capacity and state fee schedule lag, which could slow durable scaling.
Key entities
- companyNeurAxis
Reported Q2 2026 results and provided reimbursement, unit delivery, and cash/burn updates tied to Category 1 CPT implementation.
- personBrian Carrico
CEO who highlighted adoption bottlenecks (hospital capacity, state CPT fee schedule gaps) and payer decision-maker access as key challenges.
- personTimothy Henrichs
CFO who discussed expected higher cash burn in H2 as revenue growth acceleration decisions are made.
